We are live on ! Find out more
INO icon

Inovio Pharmaceuticals
INO

98 hedge funds and large institutions have $49.5M invested in Inovio Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 27 increasing their positions, 20 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 20

35% more call options, than puts

Call options by funds: $1.71M | Put options by funds: $1.27M

25% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 16

2% more funds holding

Funds holding: 96 → 98 (+2)

1.9% more ownership

Funds ownership: 31.1% → 33% (+1.9%)

24% less capital invested

Capital invested by funds: $65.1M → $49.5M (-$15.6M)

Holders
98
Holders Change
+2
Holders Change %
+2.08%
% of All Funds
1.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
27
Reduced
20
Closed
16
Calls
$1.71M
Puts
$1.27M
Net Calls
+$441K
Net Calls Change
-$506K

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.78M
2
BlackRock
BlackRock
New York
+$1.48M
3
Northern Trust
Northern Trust
Illinois
+$1.19M
4
GC
GMT Capital
Georgia
+$1.04M
5
DM
Deerfield Management
New York
+$631K

Top Sellers

1
DTC
Deep Track Capital
Connecticut
-$2.16M
2
Renaissance Technologies
Renaissance Technologies
New York
-$656K
3
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$558K
4
AGM
Alpine Global Management
New York
-$201K
5
CIC
Cornercap Investment Counsel
Georgia
-$184K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$10.9M +$1.48M +179,175 +11%
DTC
2
Deep Track Capital
Connecticut
$10.4M -$2.16M -262,354 -13%
Vanguard Group
3
Vanguard Group
Pennsylvania
$10.4M +$1.78M +216,389 +14%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$3.59M +$320K +38,833 +7%
State Street
5
State Street
Massachusetts
$2.84M +$424K +51,414 +12%
Renaissance Technologies
6
Renaissance Technologies
New York
$1.91M -$656K -79,500 -19%
Northern Trust
7
Northern Trust
Illinois
$1.19M +$1.19M +144,676 +237%
Dimensional Fund Advisors
8
Dimensional Fund Advisors
Texas
$754K +$459K +55,652 +74%
GC
9
GMT Capital
Georgia
$729K +$1.04M +126,121 New
Morgan Stanley
10
Morgan Stanley
New York
$550K -$70.7K -8,574 -8%
DM
11
Deerfield Management
New York
$442K +$631K +76,523 New
Goldman Sachs
12
Goldman Sachs
New York
$423K +$254K +30,789 +73%
Charles Schwab
13
Charles Schwab
California
$411K -$272 -33 -0%
Wellington Management Group
14
Wellington Management Group
Massachusetts
$379K +$541K +65,633 New
Bank of New York Mellon
15
Bank of New York Mellon
New York
$354K -$170K -20,622 -25%
Bank of America
16
Bank of America
North Carolina
$326K +$149K +18,109 +47%
Squarepoint
17
Squarepoint
New York
$298K +$425K +51,528 New
N
18
Nuveen
North Carolina
$269K – – –
American Century Companies
19
American Century Companies
Missouri
$236K +$76.4K +9,259 +29%
RhumbLine Advisers
20
RhumbLine Advisers
Massachusetts
$220K -$3.86K -468 -1%
Barclays
21
Barclays
United Kingdom
$197K +$207K +25,116 +283%
GAA
22
Green Alpha Advisors
Colorado
$186K -$7.18K -871 -3%
Millennium Management
23
Millennium Management
New York
$175K +$36.7K +4,450 +17%
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
$174K +$248K +30,071 New
Fidelity Investments
25
Fidelity Investments
Massachusetts
$158K +$177K +21,462 +370%
1
2 3 4 5

INO Hedge Fund Activity: Q3 2024 in Review

98 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q3 2024, worth a combined $49.5M — down 24% from $65.1M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new INO positions and 16 closed out — a net gain of 4 holders — while 27 added to existing stakes and 20 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.78M. The largest seller was Deep Track Capital, cutting an estimated $2.16M.

  • 98 institutional investors held Inovio Pharmaceuticals (INO) as of Q3 2024, up from 96 in Q2 2024.
  • Funds reported $49.5M of Inovio Pharmaceuticals stock for Q3 2024, down 24% quarter-over-quarter.
  • 20 funds opened new Inovio Pharmaceuticals positions in Q3 2024 and 16 closed out, a net change of +4 holders.
  • The largest Inovio Pharmaceuticals buyer in Q3 2024 was Vanguard Group, an estimated $1.78M added.
  • The largest Inovio Pharmaceuticals seller in Q3 2024 was Deep Track Capital, an estimated $2.16M sold.

Based on aggregated 13F filings for Q3 2024.